[go: up one dir, main page]

BR9915729A - Amidas Èmega de n-arilsulfonil-aminoácido - Google Patents

Amidas Èmega de n-arilsulfonil-aminoácido

Info

Publication number
BR9915729A
BR9915729A BR9915729-2A BR9915729A BR9915729A BR 9915729 A BR9915729 A BR 9915729A BR 9915729 A BR9915729 A BR 9915729A BR 9915729 A BR9915729 A BR 9915729A
Authority
BR
Brazil
Prior art keywords
amino acid
egamega
arylsulfonyl
amides
formula
Prior art date
Application number
BR9915729-2A
Other languages
English (en)
Inventor
Wilfried Schwab
Werner Thorwart
Manfred Schudok
Burkhard Haase
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9915729A publication Critical patent/BR9915729A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "AMIDAS ÈMEGA DE N-ARILSULFONIL-AMINOáCIDO". Compostos da fórmula (1) e/ou uma forma estereoisómerica do composto da fórmula (1) e/ou um sal fisiologicamente compatível do composto da fórmula (1) são apropriados para a preparação de medicamentos para a terapia e profilaxia de doenças, em cujo decurso participam metaloproteinases-matriz de decomposição.
BR9915729-2A 1998-11-06 1999-10-21 Amidas Èmega de n-arilsulfonil-aminoácido BR9915729A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19851184A DE19851184A1 (de) 1998-11-06 1998-11-06 N-Arylsulfonyl-aminosäure-omega-amide
PCT/EP1999/007979 WO2000027808A1 (de) 1998-11-06 1999-10-21 N-arylsulfonyl-aminosäure-omega-amide

Publications (1)

Publication Number Publication Date
BR9915729A true BR9915729A (pt) 2001-10-23

Family

ID=7886902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915729-2A BR9915729A (pt) 1998-11-06 1999-10-21 Amidas Èmega de n-arilsulfonil-aminoácido

Country Status (23)

Country Link
US (2) US6201130B1 (pt)
EP (1) EP1124797B1 (pt)
JP (1) JP4348014B2 (pt)
KR (1) KR100655632B1 (pt)
CN (1) CN1206213C (pt)
AR (1) AR021086A1 (pt)
AT (1) ATE260889T1 (pt)
AU (1) AU757602B2 (pt)
BR (1) BR9915729A (pt)
CA (1) CA2350031C (pt)
CZ (1) CZ302291B6 (pt)
DE (2) DE19851184A1 (pt)
DK (1) DK1124797T3 (pt)
ES (1) ES2213405T3 (pt)
HK (1) HK1041686B (pt)
HU (1) HUP0104122A3 (pt)
ID (1) ID28810A (pt)
PL (1) PL198827B1 (pt)
PT (1) PT1124797E (pt)
RU (1) RU2228330C2 (pt)
TR (1) TR200101245T2 (pt)
WO (1) WO2000027808A1 (pt)
ZA (1) ZA200103485B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
EP1615886A1 (en) * 2003-04-15 2006-01-18 Warner-Lambert Company LLC [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions
ES2281801T3 (es) * 2003-05-12 2007-10-01 Pfizer Products Inc. Inhibidores benzamida del receptor p2x7.
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
AU2005258911A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
KR20070115583A (ko) * 2004-06-29 2007-12-06 화이자 프로덕츠 인코포레이티드 루이스 산의 존재하에 트리아진의 4-위치에서 치환되지않은5-[4-(2-하이드록시-에틸)-3,5-다이옥소-4,5-다이하이드로-3ｈ-[1,2,4]트리아진-2-일]-벤즈아마이드 유도체와옥시란과의 반응에 의해 ｐ2ｘ7 억제 활성을 갖는 상기유도체의 제조방법
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
EP1902014A2 (en) 2005-07-11 2008-03-26 Wyeth Glutamate aggrecanase inhibitors
GT200600305A (es) 2005-10-13 2007-02-26 Métodos para preparar derivados de acido glutamico
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
AU2014214325B2 (en) * 2013-02-06 2018-06-07 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1063026A1 (ru) * 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью
JP2764262B2 (ja) 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (pt) 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
DK0766664T3 (da) 1994-06-22 2000-07-31 British Biotech Pharm Metalloproteinaseinhibitorer
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP2000500161A (ja) * 1995-06-28 2000-01-11 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー フッ素重合体のナノ複合体
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EP0901466B1 (en) * 1996-05-17 2001-10-31 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren

Also Published As

Publication number Publication date
AR021086A1 (es) 2002-06-12
ATE260889T1 (de) 2004-03-15
JP2002529447A (ja) 2002-09-10
PT1124797E (pt) 2004-07-30
CA2350031A1 (en) 2000-05-18
EP1124797A1 (de) 2001-08-22
KR100655632B1 (ko) 2006-12-12
CN1206213C (zh) 2005-06-15
ES2213405T3 (es) 2004-08-16
ZA200103485B (en) 2001-12-04
EP1124797B1 (de) 2004-03-03
CZ20011506A3 (cs) 2001-08-15
HUP0104122A2 (hu) 2002-03-28
AU1153000A (en) 2000-05-29
HK1041686A1 (en) 2002-07-19
TR200101245T2 (tr) 2001-10-22
AU757602B2 (en) 2003-02-27
RU2228330C2 (ru) 2004-05-10
PL198827B1 (pl) 2008-07-31
WO2000027808A1 (de) 2000-05-18
US6335333B1 (en) 2002-01-01
DE59908769D1 (de) 2004-04-08
JP4348014B2 (ja) 2009-10-21
US6201130B1 (en) 2001-03-13
CN1332724A (zh) 2002-01-23
KR20010080385A (ko) 2001-08-22
ID28810A (id) 2001-07-05
DK1124797T3 (da) 2004-07-05
CA2350031C (en) 2010-01-26
PL347574A1 (en) 2002-04-08
HUP0104122A3 (en) 2002-04-29
DE19851184A1 (de) 2000-05-11
HK1041686B (zh) 2005-09-23
CZ302291B6 (cs) 2011-02-09

Similar Documents

Publication Publication Date Title
BG104727A (en) Pharmaceutical composition of topiramate
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
TR200101633T2 (tr) Farmasötik bileşim
SE9901573D0 (sv) New compounds
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
BR0114344A (pt) Retinóides para o tratamento de enfisema
BR0113590A (pt) 7-oxo-piridopirimidinas
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
MXPA05013607A (es) Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0011845A (pt) Complexo farmacêutico
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
GT199900171A (es) Concentrado oral de sertralina.
PT1202956E (pt) Derivados terapeuticos e/ou nuricionalmente melhorados de ingredientes activos e composicoes de administracao oral contendo o mesmo

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ART. 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.